Question for the medical teamAnd I really would like to see JFM1330 still be on that team!
What do you take away from the ever increasing number of cancers TH-1902 is targetting? Is this simply a result of ongoing pre-clinical testing on different tumors to determine how much sortilin they are over-expressing? Have we reached the end of the additions to the list or could there be many more? What are the chances if TH-1902 works on one cancer overexpressing sortilin that it would work on all others too? I have to think it is more complicated than that. JFM1330 has previously noted the hetergeneosity of cancer tumors in humans versus the xenografts the pre-clinical work is done on. Could the sortilin factor be strong enough to overcomme the differences in tumors?